Epitalon vs TB-500 for Longevity: Which Peptide Fits Your Protocol?

What Epitalon Actually Does in the Body

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) first isolated by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology in the 1980s. Its primary proposed mechanism is activation of telomerase, the enzyme that maintains telomere length. Short telomeres are independently associated with cardiovascular disease, diabetes, and all-cause mortality. A 2003 cell-culture study published in the Bulletin of Experimental Biology and Medicine showed that Epitalon treatment increased telomerase activity and elongated telomeres in human fetal fibroblasts after repeated passage [1]. That finding has since been replicated in somatic cell lines, though no large randomized controlled trial in humans has confirmed the same effect in vivo.

Beyond telomere biology, Epitalon modulates the hypothalamic-pineal axis. Animal data from Khavinson's group showed that repeated Epitalon administration restored melatonin secretion patterns in aged rats to levels comparable to young controls [2]. Melatonin is not merely a sleep hormone. It acts as a circadian zeitgeber, an antioxidant, and an immune modulator. Declining melatonin output after age 40 correlates with accelerated oxidative stress. Restoring its secretion pattern is therefore a plausible mechanism by which Epitalon might slow age-related decline.

The most cited longevity dataset comes from a 12-year observational study in elderly residents of a St. Petersburg retirement home. Subjects who received two Epitalon cycles per year showed 28% lower all-cause mortality compared to an untreated control group over the 12-year follow-up period [3]. Observational design and the Russian research context limit how confidently one can extrapolate these numbers. Still, 28% over 12 years is a large effect size that demands replication in blinded trials.

Epitalon also shows immunomodulatory activity. A 1999 study in elderly patients found that two Epitalon treatment cycles improved T-cell activity and normalized several cytokine profiles relative to controls [4]. Given that immunosenescence (the gradual deterioration of immune function with age) is a primary driver of late-life morbidity, this pathway may be at least as clinically meaningful as the telomerase effect.

What TB-500 Actually Does in the Body

TB-500 is not the full Thymosin Beta-4 protein. It is a synthetic version of the actin-binding domain fragment (amino acids 17-23), specifically the sequence LKKTETQ. Thymosin Beta-4 itself is a 43-amino-acid peptide present in virtually every human cell and found at especially high concentrations in platelets and wound fluid. Its core function is G-actin sequestration, which governs cell migration, differentiation, and wound closure [5].

The TB-500 fragment retains much of the parent molecule's repair-related activity. Preclinical studies in rodent models show it accelerates skin wound closure, reduces cardiac fibrosis after myocardial infarction, and supports axonal regrowth following spinal cord injury [6]. A 2010 paper in the Journal of Molecular and Cellular Cardiology (Bock-Marquette et al.) showed that Thymosin Beta-4 pretreatment in mice reduced infarct size and preserved ejection fraction after coronary ligation, with effects mediated partly through Akt signaling [7]. Whether the truncated TB-500 fragment replicates all of these effects at the same magnitude remains unresolved.

For longevity applications specifically, the rationale centers on two mechanisms. First, chronic low-grade inflammation ("inflammaging") accelerates biological aging. TB-500 downregulates NF-kB pathway activity and reduces pro-inflammatory cytokines including IL-6 and TNF-alpha in multiple animal models [8]. Second, age-related loss of tissue regenerative capacity reflects declining stem cell mobilization. TB-500 promotes migration of endothelial progenitor cells and keratinocytes, which may support vascular and dermal repair that normally slows with age.

Human clinical trial data for TB-500 are sparse. Most peer-reviewed evidence remains in rodent and in-vitro models. There are no published Phase II or Phase III RCTs in humans for any TB-500 indication as of mid-2025. Clinicians using TB-500 in longevity protocols are extrapolating from mechanistic plausibility and preclinical evidence, not from the kind of controlled human data that exist for, say, semaglutide in metabolic disease.

Epitalon vs TB-500: A Direct Mechanism Comparison

These two peptides operate through almost completely different pathways, which is why the question "which one is better for longevity" misframes the choice. The right question is which biological target matters most for a given patient at a given point in time.

Epitalon targets upstream drivers of cellular aging: telomere attrition and circadian dysregulation. Its effects may be slower to manifest but potentially more durable. TB-500 targets downstream tissue injury responses: repair of damaged vasculature, muscle, neural tissue, and wound beds. Its effects tend to be more acutely apparent in patients recovering from injury or carrying high inflammatory burden.

A patient in their 50s with shortened telomeres on testing (TruAge or SpectraCell assay), elevated 8-OHdG (a urine oxidative stress marker), and disrupted melatonin rhythms on a DUTCH test is a stronger candidate for an Epitalon protocol. A patient with chronic tendinopathy, elevated CRP, post-surgical joints, or a history of cardiac ischemia may see more benefit from a TB-500 cycle first.

The two can be combined. Given the non-overlapping mechanisms, no published evidence suggests pharmacokinetic or pharmacodynamic antagonism between them. HealthRX physicians who prescribe both typically run Epitalon cycles in spring and fall (the bioregulator model used in Russian gerontology research) while using TB-500 as a 4-to-6-week repair block in response to injury or inflammatory flares.

BPC-157 vs TB-500: Which Repair Peptide Wins?

BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide derived from a protective gastric protein. TB-500 and BPC-157 are often compared because both accelerate tissue repair, but their primary targets differ.

BPC-157 shows its strongest evidence in gastrointestinal healing, tendon-to-bone junction repair, and neuroprotection via nitric oxide modulation and the FAK-paxillin pathway [9]. A 2018 review in Current Neuropharmacology cataloged over 40 animal studies showing BPC-157's ability to heal gastric ulcers, fistulas, and musculoskeletal injuries across multiple species [10]. The NO-releasing mechanism also means BPC-157 may improve blood pressure and endothelial function, an angle TB-500 does not directly address.

TB-500 acts more strongly on cardiac and neural tissue regeneration and produces broader systemic anti-inflammatory effects through actin modulation and Akt activation. BPC-157 is generally considered the first-line choice for gut pathology, intestinal permeability, and tendon injuries specifically. TB-500 is favored when the target is cardiac recovery, widespread inflammation, or neurological repair.

Used together at standard doses (BPC-157 at 250-500 mcg twice daily, TB-500 at 2 mg twice weekly), the combination appears in multiple clinical forums and has a theoretical basis in complementary mechanism, though no RCT has evaluated the stack directly.

IGF-1 vs IGF-1 LR3: Choosing the Right Growth Factor Analog

IGF-1 (Insulin-like Growth Factor 1) mediates most of growth hormone's anabolic and repair effects. Endogenous IGF-1 has a half-life of roughly 12-15 hours when bound to its binding proteins (IGFBPs), but free IGF-1 is cleared in minutes.

IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension that dramatically reduces IGFBP binding affinity. The result is a half-life of approximately 20-30 hours versus under 30 minutes for native IGF-1 [11]. In practical terms, this means a single injection of IGF-1 LR3 provides sustained receptor activation across a full day, while native IGF-1 requires either pulsatile dosing or continuous infusion for similar coverage.

For longevity applications, the IGF-1 picture is more complicated than for the repair peptides. High IGF-1 signaling through the mTOR pathway is consistently associated with accelerated aging in model organisms from C. elegans to mice [12]. The Laron syndrome phenotype (congenital IGF-1 receptor loss of function) is associated with near-zero cancer rates and extended healthspan in the Ecuadorian cohort studied by Guevara-Aguirre et al. in a 2011 Science Translational Medicine paper (N=99) [13]. This paradox means that while short-term IGF-1 LR3 cycles may support muscle repair and lean mass in the context of a broader anti-aging protocol, chronic high-dose IGF-1 signaling should probably be avoided if longevity is the primary goal. HealthRX physicians typically limit IGF-1 LR3 use to 4-week cycles at 20-40 mcg post-workout, not year-round dosing.

Semax vs Selank: Cognitive and Stress Peptides Compared

Semax and Selank were both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and share the distinction of being approved medications in Russia for neurological indications, unlike most peptides discussed in this article.

Semax is a synthetic ACTH(4-7) analog (Met-Glu-His-Phe-Pro-Gly-Pro). It increases BDNF and NGF expression within hours of administration, reduces neuroinflammation via suppression of microglial NF-kB activity, and enhances dopamine and serotonin turnover in the prefrontal cortex [14]. A 2011 Russian trial (N=187) found that intranasal Semax 0.1% reduced neurological deficit scores and improved cognitive recovery velocity in ischemic stroke patients versus placebo, with effects statistically significant at P<0.01 [15]. For healthy individuals in a longevity context, the main applications are focus enhancement, mood stabilization during high-stress periods, and neuroprotection against oxidative insult.

Selank is a synthetic analog of the immune peptide Tuftsin (Thr-Lys-Pro-Arg), extended with a stabilizing sequence. Its primary action is anxiolytic, working through GABAergic modulation and reducing degradation of enkephalins [16]. Unlike benzodiazepines, Selank does not appear to produce tolerance, dependence, or cognitive blunting at studied doses. A 2014 study in Bulletin of Experimental Biology and Medicine showed that Selank (500 mcg intranasal daily for 14 days) significantly reduced Hamilton Anxiety Scale scores in patients with generalized anxiety disorder without impairing psychomotor function [17].

The clinical distinction: Semax is the right choice for cognitive performance, BDNF-driven neuroplasticity, and stroke recovery. Selank is the right choice for anxiety reduction, sleep quality optimization, and immune modulation. Patients with both cognitive fog and anxiety sometimes cycle them together, with Selank used in the evening and Semax in the morning. There is no published pharmacokinetic interaction data for this combination, so overlap is generally kept conservative.

GHRP-2 vs Ipamorelin: Growth Hormone Secretagogues Side by Side

GHRP-2 (Growth Hormone Releasing Peptide-2) and Ipamorelin are both ghrelin-receptor agonists that stimulate pulsatile GH release from the anterior pituitary. They are often compared because they share the same final pathway but differ substantially in selectivity and side-effect profile.

GHRP-2 at standard doses (100-300 mcg subcutaneous) produces a strong GH pulse but also raises cortisol and prolactin meaningfully, in some studies by 30-50% above baseline within 60 minutes of injection [18]. Elevated cortisol in the context of an anti-aging protocol is counterproductive. Chronic cortisol elevation accelerates hippocampal atrophy, suppresses immune function, and increases visceral adiposity, which are all outcomes a longevity protocol aims to prevent.

Ipamorelin is highly GH-selective. At doses of 100-300 mcg, it produces a GH pulse comparable in amplitude to GHRP-2 but with minimal to no elevation in cortisol or prolactin in published pharmacodynamic studies [19]. A 1999 study in European Journal of Endocrinology showed that Ipamorelin was the most selective GH secretagogue tested to that point, producing GH release without triggering the ACTH/cortisol axis even at supraphysiologic doses [20]. For longevity-focused protocols where adrenal axis management matters, this makes Ipamorelin the standard choice over GHRP-2.

GHRP-2 retains a role in specific short-term contexts: GH stimulation testing (it produces a larger, more reliable peak useful for diagnostic purposes) and situations where the broader ghrelin-axis stimulation (appetite increase, gastroprotection) is a desired secondary effect. For year-round or repeated-cycle longevity use, Ipamorelin paired with a GHRH analog like CJC-1295 (without DAC) is the protocol most commonly recommended in evidence-aligned longevity medicine.

Regulatory and Safety Considerations for All Six Peptides

The FDA's November 2023 guidance placed several compounded peptides on the "difficult to compound" list, effectively restricting their availability from 503A and 503B pharmacies. BPC-157, TB-500, Semax, Selank, Ipamorelin, and Epitalon all fall into regulatory gray zones where the specific compounding rules and enforcement priorities are subject to change [21].

None of the peptides discussed in this article hold FDA approval for any human indication (with the exception of Semax and Selank in Russia and some Eastern European countries). Prescribers and patients in the United States operate under a framework where these compounds are available only through licensed compounding pharmacies under physician oversight, and even that avenue faces ongoing regulatory pressure.

The safety concerns that matter most in clinical practice are not acute toxicity events (which appear rare at studied doses across the published literature) but rather unknowns in three areas. First, oncological risk: any peptide that promotes cell proliferation, angiogenesis, or telomerase activity could theoretically accelerate pre-existing occult malignancy. Patients should have age-appropriate cancer screening before beginning a longevity peptide protocol. Second, hormonal interference: GH secretagogues including Ipamorelin and GHRP-2 may worsen insulin resistance at high doses, and IGF-1 LR3 directly stimulates the insulin receptor. Fasting glucose and HbA1c should be monitored every 3 months during use. Third, immune modulation: Thymosin Beta-4, Selank, and Epitalon all have immunomodulatory properties. Patients with autoimmune disease should approach these with caution and specialist input.

The Endocrine Society's 2019 clinical practice guideline on GH therapy states: "GH treatment in adults should be restricted to patients with confirmed growth hormone deficiency due to known causes, and routine use in healthy aging adults cannot be recommended based on current evidence." [22] That guideline applies specifically to recombinant GH, not to secretagogues, but the underlying principle of evidence-first prescribing applies to the entire class.

How to Choose Between These Peptides: A Clinical Decision Map

Patient goal and biomarker status should drive protocol selection. The following framework reflects HealthRX physician practice patterns, not published RCT-derived guidelines, and is intended for clinician review, not self-prescribing.

Patients with shortened telomeres on quantitative PCR testing, elevated 8-OHdG, or a history of age-related pineal decline (early melatonin drop on salivary testing): Epitalon is the most mechanism-matched starting point, typically 5 mg per day for 10-20 days, twice yearly.

Patients with chronic musculoskeletal injury, post-surgical recovery needs, elevated CRP above 2.0 mg/L, or evidence of impaired tissue regeneration: TB-500 loading phase (2 mg twice weekly for 4 weeks) followed by BPC-157 (500 mcg twice daily oral or subcutaneous) for ongoing gut and joint support.

Patients with cognitive decline, low BDNF on serum testing, or high-demand knowledge-work schedules: Semax 600 mcg intranasal daily for 2-4 week cycles. If anxiety or sleep disruption co-exist, add Selank 250-500 mcg intranasal in the evening.

Patients with confirmed GH deficiency on IGF-1 serum testing (IGF-1 <120 ng/mL in adults under 60), poor sleep architecture on wearable data, or significant loss of lean mass: CJC-1295 (without DAC) 100-200 mcg plus Ipamorelin 100-200 mcg at bedtime, five nights per week. GHRP-2 is not recommended for routine longevity use given its cortisol liability.

Patients interested in anabolic support for muscle repair during a timed training block: a 4-week cycle of IGF-1 LR3 at 20-40 mcg post-training. Do not layer this on top of active GH secretagogue cycles without close monitoring of fasting glucose and IGF-1 levels. Target serum IGF-1 should stay below 300 ng/mL during combined protocols.